Peptide compositions and their use against HCV

Details Peptide compositions and their use against HCV Peptide compositions and their use against HCV

2003-05-15

2008-07-01

Gupta, Anish (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C424S161100, C424S185100, C424S189100, C424S193100, C530S300000, C530S324000, C536S023500, C536S023720

Reexamination Certificate

active

07393831

ABSTRACT:
The invention relates to novel peptide compositions. In particular, the invention relates to a peptide composition comprising at least two peptides which are selected from among the following peptides: a peptide A having at least the amino acid sequence of SEQ ID No1, a peptide B having at least the amino acid sequence of SEQ ID No45, a peptide C having at least the amino acid sequence of SEQ ID No127, a peptide D having at least the amino acid sequence of SEQ. ID No174. The inventive compositions can be used, in particular, in the preparation of active pharmaceutical compositions against the hepatitis C virus.

REFERENCES:
patent: 5736321 (1998-04-01), Hosein et al.
patent: 2007/0072176 (2007-03-01), Inchauspe et al.
patent: 0 388 232 (1990-09-01), None
patent: 0 450 931 (1991-04-01), None
patent: 0 468 527 (1991-07-01), None
patent: WO 93/00365 (1993-01-01), None
patent: WO 94/20127 (1994-09-01), None
patent: WO 99/58658 (1999-11-01), None
patent: WO 99/67285 (1999-12-01), None
patent: WO 01/21189 (2001-03-01), None
patent: WO 01/030812 (2001-05-01), None
patent: WO 01/90197 (2001-11-01), None
patent: WO 01/92311 (2001-12-01), None
Kato N, Hijikata, M, Ootsuyama Y, Nakagawa M, Ohkoshi S, Sugimura T, Shimotohno K, Molecular Cloning of the Human Hepatitis C Virus Genome From Japanese Patients with Non-A, Non-B Hepatitis, Proceedings of the National Academy of Sciences of the United States of America, 1990, 87: 9524-9528.
Chang et al., “Immunological Significance of Cytotoxic T Lymphocyte Epitope Variants in Patients Chronically Infected by the Hepatitis C Virus,” J. Clin. Invest. 100:2376-2385, 1997.
Day et al., “Broad Specificity of Virus-Specific CD4+T-Helper-Cell Responses in Resolved Hepatitis C Virus Infection,” J. Virol. 76:12584-12595, 2002.
Ibe et al., “Identification and Characterization of a Cytotoxic T Cell Epitope of Hepatitis C Virus Presented by HLA-B*3501 in Acute Hepatitis,” J. Gen Virol. 79:1735-1744, 1998.
Ward et al., “Cellular Immune Responses Against Hepatitis C Virus: The Evidence Base 2002,” Clin. Exp. Immunol. 128:195-203, 2002.
Wertheimer et al., “Novel CD4+and CD8+T-Cell Determinants Within the NS3 Protein in Subjects with Spontaneously Resolved HCV Infection,” Hepatol. 37:577-589, 2003.
International Preliminary Examination Report for PCT/FR03/01478, Oct. 28, 2004 (and English language translation thereof).
International Preliminary Examination Report for PCT/FR03/01478, Oct. 28, 2004.

Affiliated with

Also associated with

Rating

Peptide compositions and their use against HCV does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptide compositions and their use against HCV, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide compositions and their use against HCV will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3968803